文献速递血管炎

风湿性多肌痛是巨细胞动脉炎更顽固性疾病的风险因素:一项回顾性队列研究

Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2024-06-28

该回顾性队列纳入2000至2020年在鲁汶大学医院(比利时)诊断并随访至少12个月的398例巨细胞动脉炎(GCA)患者,其中181例(45%)有风湿性多肌痛(PMR)症状。有PMR症状者症状持续更久、复发风险更高、糖皮质激素疗程更长且后期剂量更高,但胸主动脉瘤发生率更低。

要点

  • 有PMR症状的GCA患者复发风险更高(64% vs 51%,HR 1.38),停用糖皮质激素概率更低(62% vs 71%,HR 0.74)。
  • 有PMR症状者症状持续时间更长(11 vs 6周),发热与乏力更少见,永久性视力丧失有更少趋势(12% vs 19%,p=0.052)。
  • 两组2年累积口服糖皮质激素剂量无差异,但有PMR症状者诊断后38个月起随访期间激素剂量更高。

核心结论

  • 有PMR症状的GCA患者疾病更顽固,复发风险更高、糖皮质激素疗程更长且需要更高剂量。

研究设计与样本

  • 回顾性队列研究,纳入2000至2020年在鲁汶大学医院(比利时)连续诊断并随访至少12个月的GCA患者398例,其中有PMR症状者181例(45%)。

主要发现

  • 有PMR症状者症状持续时间更长(11 vs 6周,p<0.001),发热更少见(19% vs 28%,p=0.030),乏力更少见(52% vs 64%,p=0.015),永久性视力丧失有更少趋势(12% vs 19%,p=0.052)。
  • 2年累积口服糖皮质激素剂量两组无差异(甲泼尼龙4.4 vs 4.3 g,p=0.571)。
  • 有PMR症状者诊断后38个月起随访期间糖皮质激素剂量更高(p<0.05),停用糖皮质激素概率更低(62% vs 71%,HR 0.74 [95%CI 0.58-0.94],p=0.018),中位糖皮质激素疗程更长(29 vs 23个月,p=0.021)。
  • 有PMR症状者复发风险更高(64% vs 51%,HR 1.38 [95%CI 1.06-1.79],p=0.017),复发次数更多(1.47次 [95%CI 1.30-1.65] vs 1.16次 [95%CI 1.02-1.31],p=0.007)。
  • 有PMR症状者随访期间胸主动脉瘤发生更少(3% vs 11%,p=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate differences in presentation and outcome of giant cell arteritis (GCA) patients with and without polymyalgia rheumatica (PMR) symptoms. METHODS: Consecutive patients diagnosed with GCA between 2000 and 2020 and followed for ≥12 months at the University Hospitals Leuven (Belgium), were included retrospectively. RESULTS: We included 398 GCA patients, of which 181 (45%) with PMR symptoms. Patients with PMR symptoms had a longer symptom duration (11 vs 6 weeks, p < 0.001). They less frequently reported fever (19% vs 28%, p = 0.030) and fatigue (52% vs 64%, p = 0.015) and tended to have less permanent vision loss (12% vs 19%, p = 0.052). There was no difference in the cumulative oral GC dose at 2 years (4.4 vs 4.3 g methylprednisolone, p = 0.571). However, those with PMR symptoms were treated with higher GC doses during subsequent follow-up (p < 0.05 from 38 months after diagnosis) and had a lower probability of stopping GC (62% vs 71%, HR 0.74 [95%CI 0.58-0.94], p = 0.018) with a longer median duration of GC treatment (29 vs 23 months, p = 0.021). In addition, presence of PMR symptoms was associated with an increased risk of relapse (64% vs 51%, HR 1.38 [95%CI 1.06-1.79], p = 0.017) with a higher number of relapses (1.47 [95%CI 1.30-1.65] vs 1.16 relapses [95%CI 1.02-1.31], p = 0.007). Patients with PMR symptoms less frequently developed thoracic aortic aneurysms during follow-up (3% vs 11%, p = 0.005). CONCLUSION: GCA patients with PMR symptoms had more recalcitrant disease with a higher risk of relapse and longer duration of GC treatment with need for higher GC doses.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Moreel L, Betrains A, Boeckxstaens L, et al. Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: A retrospective cohort study. Semin Arthritis Rheum. 2024. PMID: 38968729. doi:10.1016/j.semarthrit.2024.152499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。